Press coverage about Genetic Technologies (NASDAQ:GENE) has been trending somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Genetic Technologies earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.7123526172702 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Genetic Technologies (GENE) traded down 3.15% during midday trading on Friday, reaching $0.93. The company’s stock had a trading volume of 156,076 shares. Genetic Technologies has a 1-year low of $0.70 and a 1-year high of $2.89. The company’s 50-day moving average price is $0.83 and its 200 day moving average price is $0.95. The firm’s market capitalization is $15.10 million.

ILLEGAL ACTIVITY NOTICE: “Genetic Technologies (GENE) Receiving Somewhat Positive Press Coverage, Report Finds” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/08/genetic-technologies-gene-receiving-somewhat-positive-press-coverage-report-finds.html.

About Genetic Technologies

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Insider Buying and Selling by Quarter for Genetic Technologies (NASDAQ:GENE)

Receive News & Stock Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related stocks with our FREE daily email newsletter.